MedPath

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Phase 3
Completed
Conditions
Allergic Conjunctivitis
Interventions
Drug: AC-170 0%
Drug: AC-170 0.24%
Registration Number
NCT01685242
Lead Sponsor
Aciex Therapeutics, Inc.
Brief Summary

The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • positive bilateral conjunctival allergen challenge (CAC)reaction
Exclusion Criteria
  • known contraindications or sensitivities to the study medication or its components
  • any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
  • use of disallowed medication during the period indicated prior to the enrollment or during the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AC-170 0%AC-170 0%-
AC-170 0.24%AC-170 0.24%-
Primary Outcome Measures
NameTimeMethod
Conjunctival Redness at Duration of Action (8 Hours + 30 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Conjunctival Redness at Onset of Action (15 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Ocular Itching at Onset of Action (15 Minutes Post-dose)3, 5, 7 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-dose)3, 5, 7 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Secondary Outcome Measures
NameTimeMethod
Ciliary Redness at Onset of Action (15 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

Eyelid Swelling at Onset of Action (15 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

Ear or Palate Pruritus at Duration of Action (8 Hours + 30 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

Nasal Congestion at Onset of Action (15 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

Ciliary Redness at Duration of Action (8 Hours + 30 Minutes)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

Rhinorrhea at Duration of Action (8 Hours + 30 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

Chemosis at Duration of Action (8 Hours + 30 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

Episcleral Redness at Duration of Action (8 Hours + 30 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

Chemosis at Onset of Action (15 Minutes)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

Tearing at Duration of Action (8 Hours + 30 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

Episcleral Redness at Onset of Action (15 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

Rhinorrhea at Onset of Action (15 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

Eyelid Swelling at Duration of Action (8 Hours + 30 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

Tearing at Onset of Action (15 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

Nasal Pruritus at Duration of Action (8 Hours + 30 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

Nasal Pruritus at Onset of Action (15 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

Nasal Congestion at Duration of Action (8 Hours + 30 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

Nasal Composite Score at Duration of Action (8 Hours + 30 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.

Nasal Composite Score at Onset of Action (15 Minutes Post-dose)7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.

Tolerability of Study Medication at Visit 3Aupon instillation, 1 minute and 2 minutes post instillation

Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.

Trial Locations

Locations (1)

Andover Eye Associates

🇺🇸

Andover, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath